Share This Article
Cannabis laws in the UK are filled with contradiction and corruption, yet they also offer a glimmer of hope for future change. The discussion delves into the evolution of these laws, the greed-driven approach that has led to decades of unjust persecution, and the persistent denial of the therapeutic value of cannabis despite evidence to the contrary.
The conversation sheds light on the transformation of cannabis laws in the UK, starting from its criminalisation in 1928 due to fear and ignorance. Over time, efforts to relax the laws led to the formation of the Legalized Cannabis Alliance in the early 2000s and the establishment of coffee shops and cannabis clubs. Despite public pressure, these establishments faced backlash from the media and police, with changes in cannabis classification often driven by political motivations rather than scientific evidence.
It is highlighted that the private sector and the burgeoning medical cannabis industry may have played a part in the criminalisation of cannabis while simultaneously advocating for its therapeutic benefits. Policymakers, some of whom have vested interests in cannabis companies, have been accused of ignoring recommendations from the Advisory Council for the Misuse of Drugs. There is also mention of expanding the cannabis industry to include products such as graphene, hemp cream, and biofuels.
A pivotal point in the discussion is the alleged corruption within UK cannabis laws. Policymakers have been accused of profiting from the cannabis industry while continuing to deny its therapeutic value. A correlation is drawn between the spread of myths regarding cannabis, such as the ‘skunk psychosis’ myth, and the legalisation of medical cannabis. Criticisms of cannabis laws have also drawn parallels with resistance to change witnessed in past radical movements and the Industrial Revolution.
The conversation brings to light the potential undermining of generations of cannabis activists by the medical cannabis industry, which is seen as prioritising synthetic products over natural remedies. The investments of tobacco companies like British American Tobacco and Philip Morris into the cannabis industry are explored, raising concerns about the association of cannabis with an industry known for its harm.
The prospect of the UK government legalising cannabis, albeit with restrictions, is also discussed. The conversation highlights the potential integration of cannabis into medical products and the hindrances faced by the legalisation movement, such as astroturfing and financial manipulation. Concerns are raised about the potential delays in legalisation due to changes in European licensing laws and the co-opting of the term ‘hemp’.
Attention is drawn to the importance of individual and collective efforts in standing against draconian laws and the medical cannabis industrial complex. The discussion underscores the potential benefits of legalisation, from economic gains to addressing carbon emissions through cannabis cultivation. The conversation concludes with an optimistic note, emphasising the need for unity among cannabis activists and the gradual shift towards a more accepting societal stance.
In essence, the conversation provides a comprehensive overview of the complexities surrounding the UK’s cannabis laws, touching upon the historical context, current challenges, and the hopeful path towards legalisation and fair regulation.
Watch the video below, and subscribe on YouTube to be notified of future episodes.
